<DOC>
	<DOCNO>NCT02191709</DOCNO>
	<brief_summary>Study investigate relative bioavailability orally administer dextromethorphan syrup comparison dextromethorphan ( DMP ) soft pastille healthy male female subject extensive metabolisers CYP 2D6</brief_summary>
	<brief_title>Relative Bioavailability Dextromethorphan Syrup Comparison Dextromethorphan Soft Pastilles Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age ≥18 Age ≤55 year BMI ≥18.5 BMI ≤30 kg/m2 ( Body Mass Index ) Extensive metabolisers CYP 2D6 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within one month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor TdP ( Torsades de point ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception woman childbearing potential study , i.e . sterilization , intrauterine device , hormonal contraception Lactation period Exclusion criterion specific study : Use drug inhibit induce cytochrome P 450 enzyme , especially CYP 2D6 , within 30 day prior first administration study medication trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>